Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 14;11(7):714.
doi: 10.3390/bioengineering11070714.

Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?

Francesco Dondi  1 , Alberto Miceli  2 , Guido Rovera  3 , Vanessa Feudo  4 , Claudia Battisti  5 , Maria Rondini  6 , Andrea Marongiu  7 , Antonio Mura  7 , Riccardo Camedda  8 , Maria Silvia De Feo  9 , Miriam Conte  9 , Joana Gorica  9 , Cristina Ferrari  5 , Anna Giulia Nappi  5 , Giulia Santo  10
Affiliations
Review

Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?

Francesco Dondi et al. Bioengineering (Basel). .

Abstract

Introduction: The term theragnostic refers to the combination of a predictive imaging biomarker with a therapeutic agent. The promising application of prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals in the imaging and treatment of prostate cancer (PCa) patients opens the way to investigate a possible role of PSMA-based radiopharmaceuticals in cancers beyond the prostate. Therefore, the aim of this review was to evaluate the role of 177Lu-PSMA radioligand therapy (RLT) in malignancies other than prostate cancer by evaluating preclinical, clinical studies, and ongoing clinical trials.

Methods: An extensive literature search was performed in three different databases using different combinations of the following terms: "Lu-PSMA", "177Lu-PSMA", "preclinical", "mouse", "salivary gland cancer", "breast cancer", "glioblastoma", "solid tumour", "renal cell carcinoma", "HCC", "thyroid", "salivary", "radioligand therapy", and "lutetium-177". The search had no beginning date limit and was updated to April 2024. Only articles written in English were included in this review.

Results: A total of four preclinical studies were selected (breast cancer model n = 3/4). PSMA-RLT significantly reduced cell viability and had anti-angiogenic effects, especially under hypoxic conditions, which increase PSMA binding and uptake. Considering the clinical studies (n = 8), the complexity of evaluating PSMA-RLT in cancers other than prostate cancer was clearly revealed, since in most of the presented cases a sufficient tumour radiation dose was not achieved. However, encouraging results can be found in some types of diseases, such as thyroid cancer. Some clinical trials are still ongoing, and results from prospective larger cohorts of patients are awaited.

Conclusions: The need for larger patient cohorts and more RLT cycles administered underscores the need for further comprehensive studies. Given the very preliminary results of both preclinical and clinical studies, ongoing clinical trials in the near future may provide stronger evidence of both the safety and therapeutic efficacy of PSMA-RLT in malignancies other than prostate cancer.

Keywords: PSMA; luthetium-177; non-prostate; radioligand therapy; solid tumours.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic representation of the theragnostic approach with prostate-specific membrane antigen (PSMA). The figure was created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Herrmann K., Larson S.M., Weber W.A. Theranostic Concepts: More Than Just a Fashion Trend-Introduction and Overview. J. Nucl. Med. 2017;58((Suppl. S2)):1S–2S. doi: 10.2967/jnumed.117.199570. - DOI - PubMed
    1. Weber W.A., Barthel H., Bengel F., Eiber M., Herrmann K., Schäfers M. What Is Theranostics? J. Nucl. Med. 2023;64:669–670. doi: 10.2967/jnumed.123.265670. - DOI - PubMed
    1. Hertz S., Roberts A. Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. J. Am. Med. Assoc. 1946;131:81–86. doi: 10.1001/jama.1946.02870190005002. - DOI - PubMed
    1. Kratochwil C., Haberkorn U., Giesel F.L. Radionuclide Therapy of Metastatic Prostate Cancer. Semin. Nucl. Med. 2019;49:313–325. doi: 10.1053/j.semnuclmed.2019.02.003. - DOI - PubMed
    1. Wright G.L., Jr., Haley C., Beckett M.L., Schellhammer P.F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1995;1:18–28. doi: 10.1016/1078-1439(95)00002-Y. - DOI - PubMed

LinkOut - more resources